Adjuvant Trastuzumab in HER2-Positive Breast Cancer

20112,752 citationsJournal Articlebronze Open Access

Authors

Dennis J. Slamon · University of California, Los Angeles

W. Eiermann · Krankenhaus vom Roten Kreuz

Nicholas J. Robert

Tadeusz Pieńkowski · The Maria Sklodowska-Curie National Research Institute of Oncology

Miguel Martín · Hospital Clínico San Carlos

Michael F. Press · University of Southern California

John R. Mackey · University of Alberta

Abstract

The addition of 1 year of adjuvant trastuzumab significantly improved disease-free and overall survival among women with HER2-positive breast cancer. The risk-benefit ratio favored the nonanthracycline TCH regimen over AC-T plus trastuzumab, given its similar efficacy, fewer acute toxic effects, and lower risks of cardiotoxicity and leukemia. (Funded by Sanofi-Aventis and Genentech; BCIRG-006 ClinicalTrials.gov number, NCT00021255.).

Topics & Keywords

HER2/EGFR in Cancer Research Breast Cancer Treatment Studies Cancer Treatment and Pharmacology

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 365, Issue 14, pp. 1273-1283

DOI: 10.1056/nejmoa0910383

Field-Weighted Citation Impact: 78.42